3,4-Dihydroxyphenylacetic Acid
"3,4-Dihydroxyphenylacetic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deaminated metabolite of LEVODOPA.
| Descriptor ID |
D015102
|
| MeSH Number(s) |
D02.241.223.601.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "3,4-Dihydroxyphenylacetic Acid".
Below are MeSH descriptors whose meaning is more specific than "3,4-Dihydroxyphenylacetic Acid".
This graph shows the total number of publications written about "3,4-Dihydroxyphenylacetic Acid" by people in this website by year, and whether "3,4-Dihydroxyphenylacetic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3,4-Dihydroxyphenylacetic Acid" by people in Profiles.
-
Anderson DG, Florang VR, Schamp JH, Buettner GR, Doorn JA. Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. Chem Res Toxicol. 2016 07 18; 29(7):1098-107.
-
Sengupta A, Baba K, Mazzoni F, Pozdeyev NV, Strettoi E, Iuvone PM, Tosini G. Localization of melatonin receptor 1 in mouse retina and its role in the circadian regulation of the electroretinogram and dopamine levels. PLoS One. 2011; 6(9):e24483.
-
Lubbers LS, Zafian PT, Gautreaux C, Gordon M, Alves SE, Correa L, Lorrain DS, Hickey GJ, Luine V. Estrogen receptor (ER) subtype agonists alter monoamine levels in the female rat brain. J Steroid Biochem Mol Biol. 2010 Nov; 122(5):310-7.
-
Muthian G, Mackey V, King J, Charlton CG. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Neuroscience. 2010 Sep 01; 169(3):1085-93.
-
Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol. 2009 May; 22(5):835-41.
-
Pozdeyev N, Tosini G, Li L, Ali F, Rozov S, Lee RH, Iuvone PM. Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina. Eur J Neurosci. 2008 May; 27(10):2691-700.
-
Miller LR, Mukherjee S, Ansah TA, Das SK. Cigarette smoke and dopaminergic system. J Biochem Mol Toxicol. 2007; 21(6):325-35.
-
Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, Oriaku ET, Lamango NS, Soliman KF, Charlton CG. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol Biochem Behav. 2006 Mar; 83(3):349-59.
-
Sakamoto K, Liu C, Kasamatsu M, Pozdeyev NV, Iuvone PM, Tosini G. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur J Neurosci. 2005 Dec; 22(12):3129-36.
-
Bisagno V, Ferguson D, Luine VN. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res. 2002 Jun 14; 940(1-2):95-101.